Skip to main content
. Author manuscript; available in PMC: 2018 Jul 2.
Published in final edited form as: Annu Rev Pathol. 2016 Mar 17;11:617–644. doi: 10.1146/annurev-pathol-012414-040349

Table 1.

Several approaches to generate antagonists to MDM2 and MDMX and to their interaction with p53 as well as their resultant products

Strategy Compound
Interruption of p53 interaction with MDM2 Small molecules that bind the MDM2 N′ pocket: Nutlin 3a (RG7112), MI-219, MI-63, MI-319, MI-773, AM-8553, AMG 232, benzodiazepinediones, MK-8242
Small molecules that bind the p53 N-terminal domain: RITA
Interruption of p53 interaction with MDMX Small molecules: WK 298, SJ-172550
Interruption of p53 interactions with both MDM2 and MDMX Peptidic compounds: SAH-p53s, PMI peptide, pDI peptide
Small molecules: RO-5963, CGM097
Inhibition of MDM2 ubiquitin ligase function Small molecules: HLI98, MPD, MEL23, MEL24
Inhibition of MDM2 E3 function Small molecule: JNJ-26854165
Inhibition of MDMX transcription Small molecule: NSC 207895